Edition:
United Kingdom

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

12.85USD
15 Dec 2017
Change (% chg)

$-0.05 (-0.39%)
Prev Close
$12.90
Open
$12.94
Day's High
$13.04
Day's Low
$12.73
Volume
2,233,452
Avg. Vol
765,781
52-wk High
$16.60
52-wk Low
$4.41

Latest Key Developments (Source: Significant Developments)

Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - ‍LOOK FORWARD TO POTENTIAL U.S. APPROVAL OF MIGALASTAT IN 2018​.  Full Article

Amicus Therapeutics Q3 loss per share $0.69
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Amicus Therapeutics Inc ::Amicus therapeutics announces third quarter 2017 financial results and corporate updates.Q3 loss per share $0.69.Q3 revenue $10.9 million versus I/B/E/S view $9.5 million.Q3 adjusted loss per share $0.41 excluding items.Q3 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.Amicus Therapeutics Inc - ‍reiterated full-year 2017 financial guidance​.Amicus Therapeutics Inc - ‍current cash position anticipated to fund ongoing operations into at least H2 2019​.  Full Article

Vanguard Group reports 5.85 percent passive stake in Amicus Therapeutics as of December 31, 2016
Thursday, 9 Feb 2017 

Vanguard Group Inc :Vanguard Group Inc reports a 5.85 percent passive stake in Amicus Therapeutics Inc as of December 31, 2016 -SEC filing.  Full Article

Amicus Therapeutics Q2 loss per share $0.40
Tuesday, 9 Aug 2016 

Amicus Therapeutics Inc : Amicus therapeutics announces second quarter 2016 financial results and corporate updates . Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.40 . Company expects to remain within original 2016 net cash spend guidance of between $135 million and $155 million. .Reiterated full-year 2016 net cash spend guidance.  Full Article

Amicus therapeutics says it has raised $4.7 mln in equity financing
Tuesday, 19 Jul 2016 

Amicus Therapeutics Inc :says it has raised $4.7 million in equity financing from total offering amount of $4.7 million - Sec filing.  Full Article

Amicus expands pipeline with new program for CDKl5 deficiency
Wednesday, 6 Jul 2016 

Amicus Therapeutics : Acquisition of Miamed does not impact previous full-year 2016 net cash spend guidance of $135 million to $155 million . Former shareholders of Miamed are also eligible to receive up to $65 million upon achievement of commercial milestones . Expands biologics pipeline with new preclinical program for cyclin-dependent Kinase-like 5 (cdkl5) deficiency . Obtained rights and related intellectual property to a preclinical CDKl5 program through acquisition of Miamed Inc . Amicus paid approximately $1.8 million in cash and approximately $4.7 million in amicus common stock to former shareholders of Miamed .Former shareholders of Miamed are eligible to receive up to $18 million upon achievement of clinical and regulatory milestones.  Full Article

Amicus Therapeutics recieves European Commission approval for Galafold
Tuesday, 31 May 2016 

Amicus Therapeutics Inc : Amicus Therapeutics announces European Commission approval for Galafold (Migalastat) in patients with Fabry Disease in European Union .Amicus Therapeutics says European Commission approval for Galafold in patients with Fabry Disease.  Full Article

BRIEF-Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat

* AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE